Key Metrics 
Check Before You Invest 
10 Yrs X-Ray 
Profit & Loss 
Valuation 
Analyst Note 
Balance Sheet 
Cash Flow 
Financial Ratio 
Qtr. Results 
News 
About
Wockhardt Ltd (WOCKPHARMA)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 532300 NSE: WOCKPHARMA Pharmaceuticals & Drugs | Small Cap | Wockhardt Share Price
₹1,849.90 0.75 (0.04%)
As on 24-Jul'26 16:59
Wockhardt Ltd (WOCKPHARMA)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 532300 NSE: WOCKPHARMA Pharmaceuticals & Drugs | Small Cap | Wockhardt Share Price
₹1,849.90 0.75 (0.04%)
As on 24-Jul'26 16:59
Key Metrics
Valuation Multiples
Market Cap
₹30,059 Cr.
Current Price
₹1,849.9
52-Week Low / High
₹1,087 / 2,420
TTM EPS
₹13.1
TTM Sales
₹3,373 Cr.
Book Value per Share
₹303.2
P/E Ratio
141.12
Industry PE
52.9
Price to Book (P/B)
6.10
Higher than its 5-year historical median
Price to Sales (P/S)
8.91
Higher than its 5-year historical median
EV/EBITDA
41.85
In line with its 5-year historical median
Dividend Yield
0%
Profitability Efficiency
Return on Equity (ROE)
4.29%
Underperforms industry median
Return on Capital Employed (ROCE)
6.79%
Underperforms industry median
Return on Assets (ROA)
2.53%
Operating Profit Margin
18.6%
Net Profit Margin
5.9%
Gross Profit Margin
14.2%
Growth Momentum
1-yr vs 3-yr growth
1-yr vs 3-yr growth
Sales Growth (1 Year)
Improving versus 3-year growth rate
11.99%
Operating Profit Growth (1 Year)
Slowing versus 3-year growth rate
59.29%
Net Profit Growth (1 Year)
-
-
Asset Quality
Promoter Holding
49.08%
Pledged shares (%) of Promoter's holding (%)
14.68%
Reserves
₹4,846 Cr.
Equity
₹81.3 Cr.
Face Value
₹5
All Time Low / High
₹62.20 / 2420.00
Check Before You Invest
Quality
Not GoodValuation
OvervaluedCheck Valuation charts
Price Trend
Semi Strong
Is Wockhardt Ltd a good quality company?
Wockhardt Ltd is a weak quality company, based on a inconsistent multi-year financial track record.
This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.
We have analysed the performance of the company on the following:
-
How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
-
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
-
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.
How does Wockhardt Ltd performance compare with that of its Peers?
Revenue growth of Wockhardt Ltd vs industry peers?
Wockhardt Ltd revenue CAGR is 4.49%, compared to the industry median CAGR of 5.34%, indicating slower growth and losing its market share.
Promoter shareholding and pledge status of Wockhardt Ltd?
Promoters hold 49.08% of the Wockhardt Ltd, with 14.68% of their stake pledged, indicating high pledge risk.
Stock return of Wockhardt Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of 7.4% based on the current price.
10 Year X-Ray :
Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year endData adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
What is a Financial Track Record? How to read this chart in order to understand the data present here?
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Wockhardt Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good
Value Creation ⓘ
| Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | -0.3% | -5.5% | -2.9% | -1.1% | -5.5% | -2% | -5.9% | -2.2% | 4.1% | 6.8% | - |
| Value Creation Index ⓘ | -1.0 | -1.4 | -1.2 | -1.1 | -1.4 | -1.1 | -1.4 | -1.2 | -0.7 | -0.4 | - |
Growth Parameters ⓘ |
|||||||||||
| Sales ⓘ | 4,015 | 3,937 | 3,566 | 2,844 | 2,708 | 3,230 | 2,651 | 2,798 | 3,012 | 3,373 | 3,373 |
| Sales YoY Gr. | - | -1.9% | -9.4% | -20.2% | -4.8% | 19.3% | -17.9% | 5.6% | 7.7% | 12% | - |
| Adj EPS ⓘ | -17.9 | -37.1 | -22.6 | -14.9 | -22 | -8.6 | -29.8 | -27.3 | -2.9 | 13.5 | 13.1 |
| YoY Gr. | - | NA | NA | NA | NA | NA | NA | NA | NA | NA | - |
| BVPS (₹) ⓘ | 275.1 | 234.5 | 220 | 219.8 | 280.5 | 266 | 231.8 | 217.3 | 268 | 304.1 | 303.2 |
| Adj Net Profit ⓘ | -215 | -445 | -272 | -179 | -265 | -124 | -429 | -418 | -46.3 | 219 | 213 |
| Cash Flow from Ops. ⓘ | -269 | 68.4 | 183 | 649 | -287 | 413 | 153 | 219 | -22 | 390 | - |
| Debt/CF from Ops. ⓘ | -15.4 | 54.8 | 18.4 | 5 | -8.1 | 4.5 | 12.3 | 9.6 | -84.5 | 5.5 | - |
CAGR ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | -1.9% | 4.5% | 8.4% | 12% | ||||
| Adj EPS ⓘ | NA | NA | NA | NA | ||||
| BVPSⓘ | 1.1% | 1.6% | 9.5% | 13.5% | ||||
| Share Price | 7.6% | 29.6% | 99.6% | 10.4% | ||||
Key Financial Parameters ⓘ
| Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | -6 | -14.4 | -9.8 | -6.7 | -8.8 | -3.4 | -11.9 | -12.5 | -1.2 | 4.7 | 4.3 |
| Op. Profit Mgn % ⓘ | 0.7 | -1.4 | -0.4 | 3.4 | -2.3 | 9.2 | 3.9 | 3.3 | 13.2 | 18.6 | 19.5 |
| Net Profit Mgn % ⓘ | -6.1 | -12.8 | -8.3 | -5.4 | -9.7 | -4.9 | -18.5 | -15.3 | -1.9 | 6.1 | 6.3 |
| Debt to Equity ⓘ | 1.3 | 1.3 | 1.3 | 1.2 | 0.7 | 0.5 | 0.6 | 0.6 | 0.4 | 0.4 | 0.3 |
| Working Cap Days ⓘ | 242 | 233 | 255 | 320 | 180 | 161 | 188 | 198 | 185 | 203 | 138 |
| Cash Conv. Cycle ⓘ | 134 | 116 | 114 | 130 | 37 | 10 | -7 | 15 | 25 | 55 | 51 |
Profit And Loss
(All Figures are in Crores.)| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 4,015 | 3,937 | 3,566 | 2,844 | 2,708 | 3,230 | 2,651 | 2,798 | 3,012 | 3,373 |
| Operating Expenses ⓘ + | 4,002 | 3,992 | 3,604 | 2,746 | 2,771 | 2,932 | 2,550 | 2,759 | 2,619 | 2,747 |
| Operating Profit ⓘ | 13 | -55 | -38 | 98 | -63 | 298 | 101 | 39 | 393 | 626 |
| Operating Profit Margin (%) | 0.3% | -1.4% | -1.1% | 3.4% | -2.3% | 9.2% | 3.8% | 1.4% | 13.0% | 18.6% |
| Other Income ⓘ + | 114 | 177 | 21 | 60 | 132 | 20 | 122 | 83 | 62 | 137 |
| Interest ⓘ | 225 | 255 | 265 | 276 | 249 | 299 | 302 | 305 | 254 | 213 |
| Depreciation ⓘ | 149 | 150 | 164 | 224 | 246 | 247 | 251 | 223 | 217 | 227 |
| Profit Before Tax ⓘ | -247 | -641 | -447 | -342 | -568 | -411 | -624 | -420 | -16 | 238 |
| Tax ⓘ | -21 | 26 | -135 | -204 | -271 | -132 | -3 | 52 | 41 | 39 |
| Profit After Tax | -226 | -667 | -312 | -138 | -297 | -279 | -621 | -472 | -57 | 199 |
| PAT Margin (%) | -5.6% | -16.9% | -8.7% | -4.9% | -11.0% | -8.6% | -23.4% | -16.9% | -1.9% | 5.9% |
| Adjusted EPS (₹) | -16.3 | -50.7 | -16.2 | -5.8 | 57.5 | -16.9 | -38.8 | -30.1 | -2.9 | 13.2 |
| Dividend Payout Ratio (%) | -56.50% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Valuation of Wockhardt - Consolidated
Analyst's Notes
No data found!
Balance Sheet
(All Figures are in Crores.)| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | |||||||||||
| Shareholders Fund + | 3,300 | 2,815 | 2,643 | 2,642 | 3,348 | 3,831 | 3,338 | 3,346 | 4,342 | 4,927 | |
| Debt + | 3,853 | 2,610 | 2,453 | 2,145 | 1,569 | 1,389 | 1,554 | 1,723 | 1,707 | 1,956 | |
| Minority Interest | 382 | 346 | 330 | 386 | 383 | 353 | 308 | 303 | 304 | 341 | |
| Trade Payables | 534 | 602 | 840 | 895 | 696 | 921 | 867 | 766 | 592 | 563 | |
| Others Liabilities ⓘ | 780 | 1,605 | 1,305 | 1,682 | 1,380 | 1,176 | 1,008 | 932 | 641 | 351 | |
| Total Liabilities ⓘ | 8,849 | 7,978 | 7,571 | 7,749 | 7,376 | 7,670 | 7,075 | 7,070 | 7,586 | 8,138 | |
Fixed Assets | |||||||||||
| Net Fixed Assets ⓘ + | 2,773 | 2,888 | 3,058 | 3,502 | 3,343 | 3,462 | 3,042 | 2,881 | 2,736 | 2,791 | |
| CWIP ⓘ | 1,244 | 1,433 | 1,445 | 1,585 | 1,379 | 1,342 | 1,539 | 1,722 | 2,033 | 2,379 | |
| Investments ⓘ | 563 | 214 | 0 | 0 | 0 | 0 | 0 | 0 | 422 | 412 | |
| Inventories | 1,108 | 856 | 819 | 716 | 799 | 769 | 658 | 640 | 725 | 887 | |
| Trade Receivables | 1,034 | 962 | 1,274 | 1,243 | 918 | 918 | 797 | 618 | 661 | 588 | |
| Cash Equivalents | 1,604 | 1,082 | 449 | 268 | 292 | 406 | 124 | 529 | 191 | 250 | |
| Others Assets ⓘ | 524 | 544 | 525 | 435 | 645 | 773 | 915 | 680 | 818 | 831 | |
| Total Assets ⓘ | 8,849 | 7,978 | 7,571 | 7,749 | 7,376 | 7,670 | 7,075 | 7,070 | 7,586 | 8,138 | |
Cash Flow
(All Figures are in Crores.)| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ + | -269 | 68 | 183 | 649 | -287 | 413 | 153 | 219 | -22 | 390 |
| Cash Flow From Investing Activity ⓘ + | -687 | 630 | 95 | -156 | 1,470 | -201 | -125 | -137 | -783 | -241 |
| Cash Flow From Financing Activity ⓘ + | 1,254 | -769 | -776 | -680 | -1,171 | -71 | -315 | 334 | 409 | -54 |
| Net Cash Flow ⓘ | 298 | -71 | -499 | -186 | 12 | 141 | -287 | 416 | -396 | 95 |
Financial Ratio
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | -6.42 | -21.81 | -11.43 | -5.22 | -9.92 | -7.77 | -17.32 | -14.12 | -1.48 | 4.29 |
| ROCE (%) | -0.31 | -5.47 | -2.87 | -1.11 | -5.5 | -1.96 | -5.88 | -2.15 | 4.07 | 6.79 |
| Asset Turnover Ratio | 0.48 | 0.47 | 0.46 | 0.37 | 0.61 | 0.68 | 0.58 | 0.51 | 0.53 | 0.49 |
| PAT to CFO Conversion(x) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 1.96 |
| Working Capital Days | ||||||||||
| Receivable Days | 97.60 | 92.60 | 114.50 | 161.50 | 85 | 65.30 | 73.30 | 71.60 | 60.40 | 58.80 |
| Inventory Days | 100.50 | 91 | 85.70 | 98.50 | 59.60 | 55.80 | 61 | 65.70 | 64.40 | 75.80 |
| Payable Days | 128.60 | 115.30 | 160.80 | 263.20 | 255.90 | 232.90 | 293.70 | 255.80 | 218.90 | 186.20 |
Management X-Ray
Shareholding Pattern
Promoter's Holding & Share Pledging
| Pledged * | 52.90 | 37.47 | 33.64 | 16.98 | 18.24 | 15.64 | 21.30 | 18.04 | 18.82 | 14.68 |
* Pledged shares as % of Promoter's holding (%)
Top 5 Mutual Funds Holding
Last Visited Stocks
Announcements
Wockhardt Ltd FAQs
The current trading price of Wockhardt on 24-Jul-2026 16:59 is ₹1,849.9.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 23-Jul-2026 the market cap of Wockhardt stood at ₹30,059.4 Cr
The latest P/E ratio of Wockhardt as of 23-Jul-2026 is 94.82.
The latest P/B ratio of Wockhardt as of 23-Jul-2026 is 9.78.
The 52-week high of Wockhardt is ₹2,420 and the 52-week low is ₹1,086.8.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Wockhardt is ₹1,739 ( Cr.) .
Past 10 year’s financial track record analysis by Moneyworks4me indicates that Wockhardt Ltd is a below average quality company.
The key valuation ratios of Wockhardt Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Wockhardt Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.
About Wockhardt Ltd
Wockhardt is a global pharmaceutical and biotechnology organisation, providing affordable, high-quality medicines for a healthier world. It is India’s leading research-based global healthcare enterprise with relevance in the fields of Pharmaceuticals, Biotechnology and a chain of advanced Super Speciality Hospitals. It is a true Indian Multi-National Company with a multi-ethnic workforce of many Wockhardt Associates from many different nationalities globally. It has many research centres and several manufacturing plants, with businesses ranging from the manufacture and marketing of Pharmaceutical and Bio-pharmaceutical formulations, Active Pharmaceutical Ingredients (APIs) and Vaccines.
Business area of the company
The company is a pharmaceutical and biotechnology company. The company's businesses include manufacture and marketing of pharmaceutical and bio-pharmaceutical formulations, active pharmaceutical ingredients (APIs) and vaccines.
Businesses of the company
- New drug discovery
- Branded pharmaceuticals
- Contract manufacturing
- Biologicals in diabetes
- Vaccines
- API
Awards
2009
- Outstanding National Citizen Award by National Citizens Guild.
- Strathmore’s Who’s Who - Social Entrepreneur of the Year.
2010
- AmeriCares India Spirit of Humanity Award.
- USA BF Foundation of the Year Award.
- HEF Award for ‘Outstanding contribution to the teaching community with special reference to Human Values.
- Best Pharma CSR award at the Pharmaceutical Leadership Summit.
2011
- IDF - CSR Award.
2012
- Inclusive India Award under the Corporate category for ‘Best Social Work in the Realm of Primary Healthcare’.
- IPE CSR Corporate Governance Award.
2013
- Rajiv Gandhi Global Excellence Award.
- Rajiv Gandhi Excellence Award.
- Bharat Gaurav Award.
- Asian CSR Leadership Awards.
- CSR Excellence & Leadership Award.
- Asia Peace Award.
2015
- Best CSR Project in Healthcare for Mobile 1000 Medical vans - India CSR.
- Best Community Development Award for Mobile 1000 - World CSR Congress.
- CSR Professional of the Year - World CSR Congress.
- Maharashtra Class Owners Association Meritorious Award for valuable contribution in the field of education.
- Bronze Award for Table Calendar - A.B.C.I (Association of Business Communicators of India).
- Social Entrepreneur of the Year 2015 - Pharma Leaders.
- Swachh Bharat Samman - India CSR.
- Best Environment Friendly Project for Bio-Toilets - Asian CSR Leadership Awards.
2016
- CSR Leadership Award.
- Lions CSR Precious Award.
- Champion of WSIS Prize 2016 - World Summit on the Information Society.
- Outstanding Leadership Award - Nurturing the Future Foundation.
- Peace Leader of the Year 2016 - 7th India Leadership Conclave and Indian Affairs Business Leadership Awards 2016.
- Best Service Award for Significant National Contribution - Institute of Technology & Science.
- Asia Healthcare Excellence Award - CMO Asia.
2017
- Excellence Award for Corporate Social Responsibility & Peace Mission - Indian Virtual University for Peace and Education (IVUP).
- Global NGO Excellence Award for Excellence in Mother & Child Care - World CSR Day.
- CSR Humanity Award’ by India CSR.
- Lifetime Achievement Award from the National Institute of Cleanliness Education and Research (NICER).
- Indian of the Year 2017 (Social Service) by ILC Power Brand.
- The Rotary Peace Ambassador Award by Rotary.
- CSR Impact Award by IndiaCSR.
- Magnificient Man Choice Award with specialization in CEO CSR Excellence from Hopewill International Business Academy.
2018
- Game Changer Award by The HR Club.
- Sabarmati Festival Foundation Award for Outstanding Social Work from Sabarmati Festival Foundation.
- Divyang Ratna Award 2018 by Disable Welfare Trust of India.
2019
- Mumbai Heroes Award from Blossom Media Pvt Ltd at the Humanity First Conclave.
- Inspiring Indian Award from Indian Ex Defence Service Employees Chamber of Commerce & Industries (IESECCI).
- Award for Peace Mobilization from Poddar Foundation at the Insure your Mental Health Conference (Celebrating World Health Day).
- Inspirational Indian of the Year at the The Mumbai Achievers Awards 2019 by Mumbai Halchal.
- Bharat Shree Award 2019.
- Rotary Award from Rotary Club of Mumbai Khar.
- H F F Excellence Award from Humanity First Foundation.
2020
- ‘For the Sake of Honour’ Award from Rotary.
- Excellence in Human Welfare Award from Charity with a Twist, Nargis Dutt Foundation, ECOMO.
2024
- Dr. Habil Khorakiwala bestowed Lifetime Achievement award by Integrated Health and Wellbeing Council in Dubai
- Wockhardt wins prestigious innovator award from Government of India.
Milestones
- 1967: Wockhardt founded by Dr. Habil Khorakiwala.
- 1972: Launch of PROXYVON - the first combination formulation in pain management.
- 1979: First in India to bring POVIDONE IODINE (BETADINE) to manage sepsis in collaboration with Mundi Pharma of Switzerland.
- 1979: First modern manufacturing plant commissioned at Chikalthana, Chhatrapati Sambhajinagar.
- 1995: First UK MCA and Australia TGA approval received.
- 1999: Incorporated as Wockhardt Ltd. and listed on the stock exchange.
- 2000: First recombinant product BIOVAC-B launched.
- 2003: Acquisition of CP Pharmaceuticals, UK.
- 2005: Launches India's 1st automatic insulin delivery device: WOSULIN PEN + Cartridges.
- 2005: Only pharmaceutical company in India to be recognised as 'Business Superbrand'.
- 2006: Acquisition of Pinewood Healthcare, Ireland.
- 2007: Acquisition of Morton Grove Pharmaceuticals, USA, & Negma, France.
- 2009: Wins Government of India Patent Award.
- 2013: Wins ‘Best Enterprise’ Award from Europe Business Assembly, Oxford, UK.
- 2017: Celebrates 50 Golden Years.
- 2018: Manufacturing and R&D unit in Dubai.
- 2020: 1st Indian Company to Achieve Approval for EMROK & EMROK O.
- 2020: QIDP for WCK 6777.
- 2020: Wockhardt partners with UK government for COVID-19 vaccine fill & finish.
- 2021: Wockhardt & Jemincare partner for novel respiratory antibiotic Nafithromycin.
- 2022: NIH, USA to conduct human Phase 1 trial of Wockhardt’s novel antibiotic WCK 6777.
- 2022: Wockhardt & Serum Life Sciences UK announce collaboration for manufacturing multiple vaccines in UK.
- 2024: CLSI awards high susceptibility breakpoints to Zaynich, Wockhardt's novel proprietary antibiotic.
- 2024: WCK 6777 granted Fast Track designation by USFDA, completes Phase I study conducted by NIH, US.
- 2025: Zaynich achieves highest-ever efficacy meeting superiority in a global, pivotal, registration enabling Phase III study in cUTI achieving 96.8% clinical cure rate.
- 2025: Zaynich – Global Phase III clinical study completed.
- 2025: Zaynich – NDA submission completed with the US FDA.
- 2026: Files Marketing Authorisation Application for WCK 5222 with European Medicines Agency.
You have 4 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
